Approaching COVID-19 with epidemiological genomic surveillance and the sustainability of biodiversity informatics in Africa.
Africa
COVID variants
COVID-19 pandemic
SARS-CoV-2 infection
biodiversity
bioinformatics
genomic surveillance
phylogenetics
Journal
Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
revised:
09
11
2022
received:
03
08
2022
accepted:
10
11
2022
pubmed:
14
11
2022
medline:
11
1
2023
entrez:
13
11
2022
Statut:
ppublish
Résumé
COVID-19 is an acute respiratory illness caused by Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2). The first case was reported in Africa on February 14, 2020 and has surged to 11 million as of July 2022, with 43% and 30% of cases in Southern and Northern Africa. Current epidemiological data demonstrate heterogeneity in transmission and patient outcomes in Africa. However, the burden of infectious diseases such as malaria creates a significant burden on public health resources that are dedicated to COVID-19 surveillance, testing, and vaccination access. Several control measures, such as the SHEF2 model, encompassed Africa's most effective preventive measure. With the help of international collaborations and partnerships, Africa's pandemic preparedness employs effective risk-management strategies to monitor patients at home and build the financial capacity and human resources needed to combat COVID-19 transmission. However, the lack of safe sanitation and inaccessible drinking water, coupled with the financial consequences of lockdowns, makes it challenging to prevent the transmission and contraction of COVID-19. The overwhelming burden on contact tracers due to an already strained healthcare system will hurt epidemiological tracing and swift counter-measures. With the rise in variants, African countries must adopt genomic surveillance and prioritize funding for biodiversity informatics.
Identifiants
pubmed: 36372783
doi: 10.1002/jmv.28308
pmc: PMC9878081
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e28308Informations de copyright
© 2022 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC.
Références
Drug Discov Ther. 2020;14(4):153-160
pubmed: 32908070
Int J Health Plann Manage. 2022 Jan;37(1):14-20
pubmed: 34580911
J Med Virol. 2022 May;94(5):1825-1832
pubmed: 35023191
Science. 2022 Jan 07;375(6576):43-50
pubmed: 34812653
Hum Vaccin Immunother. 2021 Oct 3;17(10):3491-3494
pubmed: 34161189
N Engl J Med. 2022 Apr 7;386(14):1314-1326
pubmed: 35196424
J Med Virol. 2020 Nov;92(11):2465-2472
pubmed: 32525568
Pan Afr Med J. 2020 Sep 03;37(Suppl 1):3
pubmed: 33294104
Nat Rev Immunol. 2021 Aug;21(8):469-470
pubmed: 34168345
Science. 2014 Sep 12;345(6202):1369-72
pubmed: 25214632
Vaccine. 2008 Sep 12;26 Suppl 4:D31-4
pubmed: 19230156
Lancet Microbe. 2021 Sep;2(9):e481-e484
pubmed: 34337584
N Engl J Med. 2022 May 12;386(19):1855-1857
pubmed: 35385628
J Med Virol. 2023 Jan;95(1):e28308
pubmed: 36372783
Clin Epidemiol Glob Health. 2021 Oct-Dec;12:100841
pubmed: 34368503
Malar J. 2020 Dec 23;19(1):457
pubmed: 33357220
Am J Trop Med Hyg. 2021 Feb 11;104(4):1179-1187
pubmed: 33571138
Nature. 2022 May;605(7911):619
pubmed: 35610376
Int J Infect Dis. 2021 Feb;103:469-477
pubmed: 33333248
Lancet Glob Health. 2020 Jul;8(7):e881-e883
pubmed: 32530422
BMC Ecol. 2013 Apr 15;13:16
pubmed: 23587026
Science. 2021 Oct 22;374(6566):423-431
pubmed: 34672751
Emerg Microbes Infect. 2022 Dec;11(1):337-343
pubmed: 34935594